[3] Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in pati ents with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gas...
[10]Sheffield KM, Peachey JR, Method M, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022 Jul;18(21):2667-2682 [11]JOHANSSON A L V, TREWIN C B, HJERKIND K V, et al. ...
Event-free survival GM-CSF: Granulocyte macrophage colony-stimulating factor HER2+: Human epidermal growth factor 2 positive HLA: Human leukocyte antigen HR: Hormone receptors ICD: Intra-cellular domain IFN-γ: Interferon gamma IgG: Immunoglobulin G IHC: Immunohistochemistry LPBC: Lymphocyt...
Treatment with anti-programmed cell death protein 1 (PD-1) therapy and chemotherapy prolongs the survival of patients with unresectable advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. The benefit from anti-PD-1 therapy is enriched in patients with programmed cell death...
[5]L. Arecco, M.M. Latocca, E. Blondeaux, et al. Adjuvant endocrine therapy choices in premenopausal patients with estrogen receptor-positive early breast cancer: insights from the GIM23-POSTER study, 2024 EBCC. ...
Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br. J. Cancer 111, 1532–1541 (2014). Article CAS PubMed PubMed Central Google Scholar Pascual, T. et al. Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormone receptor-positive...
It was recently reported that the median overall survival (OS) in a cohort of patients with HER2-positive MBC who were treated with trastuzumab between 1999 and 2005 was 3.5 years from the time of initiation of therapy in the metastatic setting (Olson et al, 2013). However, despite improved...
This demonstrated that high HIF-2α expression is associated with disease-specific survival in HER2-positive tumours (P = 0.0197, HR = 6.81, at the most significant cut-point). A total of 56 out of 235 cut-points (23.8%) were significant (P < 0.05) (grey bar in Fig. ...
DESTINY-Lung05 II期临床研究的分析结果显示,优赫得®5.4mg/kg剂量方案的客观缓解率为58.3%;经研究者评估的PFS为10.8个月。可控的安全性证实了5.4mg/kg是治疗既往接受过治疗的HER2突变晚期肺癌患者的最佳剂量。 上海2024年4月10日/美通社/ -- 在4月5日-4月10日举办的第115届美国癌症研究协会(AACR)年会期间,...
Five measures of T-DXd for HER2+ UBC/MBC 347 clinical effectiveness were specified in the final scope: over- all survival (OS), progression-free survival (PFS), response rate, adverse events (AEs) and health-related quality of life (HRQoL). T-DXd received a licence extension for the ...